Telmisartan 40 mg + Metoprolol Succinate 25 mg + Chlorthalidone 12.5 mg Tablet combines an angiotensin II receptor blocker (telmisartan) that relaxes blood vessels, a cardioselective beta-blocker (metoprolol succinate ER) that reduces heart rate and cardiac output, and a thiazide-like diuretic (chlorthalidone) that promotes natriuresis to achieve synergistic blood pressure reduction.
Triple fixed-dose therapy provides superior BP control ( 28-32/15-18 mmHg) in resistant hypertension patients uncontrolled on dual therapy, reducing stroke risk by 35-40%, HF hospitalization by 30%, and target organ damage while improving medication adherence.